STOCK TITAN

Aurora Cannabis Inc. Common Shares - ACB STOCK NEWS

Welcome to our dedicated page for Aurora Cannabis Common Shares news (Ticker: ACB), a resource for investors and traders seeking the latest updates and insights on Aurora Cannabis Common Shares stock.

Aurora Cannabis Inc. (NASDAQ: ACB, TSX: ACB) is a prominent Canadian company headquartered in Edmonton, Alberta, dedicated to the cultivation, production, and sale of high-quality cannabis for both medical and recreational use. The company's state-of-the-art facilities in Alberta embody advanced cultivation techniques that ensure the highest standards of quality, reliability, and safety in their products. Aurora's comprehensive portfolio includes renowned brands like Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, catering to a wide range of consumer preferences.

Aurora's operations extend beyond Canada, with significant international presence through medical cannabis exporting agreements. A notable subsidiary, Australis Capital Inc., plays a crucial role in participating in the U.S. cannabis market. The company's commitment to quality is further highlighted by its EU-GMP and TGA-GMP certified production facilities, ensuring compliance with rigorous international standards.

In recent developments, Aurora has launched three new cannabis-infused beverages targeted initially at veteran patients. These products, featuring innovative SōRSE® emulsion technology, offer an alternative form of cannabis consumption without the strong cannabis aroma or taste. Available in flavors like Neon Rush, Strawberry Pineapple Tropical Fizz, and Pineapple Coconut Fizz, these beverages are designed to enhance patient wellbeing with a refreshing and potent experience.

Financially, Aurora has achieved significant milestones, including the repayment of nearly $465 million in convertible debt and forecasting positive free cash flow for calendar 2024. The company has also strengthened its global footprint by acquiring MedReleaf Australia's majority equity, further solidifying its position in the Australian market. Aurora’s commitment to financial discipline and strategic expansions underscores its potential for sustainable growth.

Aurora's dedication to innovation and patient care is exemplified through its continuous development of new products and partnerships. Their recent launches include resin cartridges and pastilles in Australia, expanding their product range and enhancing patient access to premium medical cannabis. Additionally, the company's strategic moves in Europe, particularly in Germany, position it as a leader in the evolving cannabis landscape.

With a robust pipeline of products and strategic market expansions, Aurora Cannabis Inc. continues to pave the way for significant advancements in the global cannabis industry, committed to improving lives through high-quality, innovative cannabis products.

Rhea-AI Summary
Aurora Cannabis Inc. has acquired the remaining 90% equity interest of MedReleaf Australia for AUD$50 million, making it the largest global medical cannabis company operating in nationally legal markets. The transaction is expected to be immediately accretive to Adjusted EBITDA and accelerate the Company's plan for Positive Free Cash Flow generation in 2024. The Australian medical cannabis market is rapidly growing and is estimated to be worth approximately AUD$400 million, with MedReleaf Australia holding the #2 position in the market. The acquisition is a strategic milestone for Aurora, strengthening its presence in Australia and supporting its path to profitability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.03%
Tags
-
Rhea-AI Summary
Aurora Cannabis Inc. re-affirms its expectation of positive annual Adjusted EBITDA for fiscal 2024 and positive Free Cash Flow generation in calendar 2024. The company also announces its intention to consolidate common shares and schedules its Q3 2024 investor conference call for February 8, 2024. Adjusted EBITDA is expected to be positive on an annual basis in fiscal 2024, and management continues to expect positive free cash flow in calendar 2024. The Board of Directors has approved a plan to consolidate all outstanding Common Shares on the basis of 1 Common Share for every 10 Common Shares currently outstanding.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.04%
Tags
-
Rhea-AI Summary
Aurora Cannabis Inc. (ACB) announces the launch of three new cannabis-infused beverages exclusively for veteran patients, available at Aurora Medical. The products, produced by Vacay and Versus, offer THC, CBD, and CBG options in three fruity flavors. The company aims to meet the needs of patients seeking alternative forms of cannabis to support their wellbeing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.31%
Tags
none
Rhea-AI Summary
Aurora Cannabis Inc. (ACB) achieved record positive adjusted EBITDA of $3.4 million, with quarterly net revenue rising 30% YoY to $63.4 million. The company also has a net cash position of over $200 million and expects to repay the remaining US$5.3 million balance of Convertible Senior Notes in February 2024. The Q2 2024 results show strong growth in global medical cannabis and a positive outlook for achieving positive free cash flow in calendar year 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.62%
Tags
-
Rhea-AI Summary
Aurora Cannabis Inc. has scheduled a conference call to discuss its second quarter fiscal year 2024 results on November 9, 2023. The call will be hosted by the CEO and CFO. Aurora is a pioneer in the global cannabis market, serving both medical and consumer markets. The company's brands include Aurora Drift, San Rafael '71, Daily Special, Tasty's, Whistler, Being, and Greybeard. Aurora's common shares trade on the NASDAQ and TSX under the symbol 'ACB'.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.56%
Tags
conferences earnings
-
Rhea-AI Summary
Aurora Cannabis announces settlement of patent litigation
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.85%
Tags
none
Rhea-AI Summary
Aurora Cannabis Inc. closes bought deal offering, saving almost C$2 million in annual interest payments
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.11%
Tags
none
-
Rhea-AI Summary
Aurora Cannabis launches new brand TASTY'S promising great product and taste. Includes 50% THC pre-rolls and 1,000mg vapes. Targets pre-roll segment growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
none
-
Rhea-AI Summary
Aurora Cannabis Inc. receives approval to transfer listing to Nasdaq Capital Market and agrees to repurchase $9.6 million worth of convertible notes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
buyback
Rhea-AI Summary
Aurora Cannabis repurchases $12.3 million of convertible senior notes, reducing debt and annual cash interest costs
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
72.21%
Tags
buyback

FAQ

What is the current stock price of Aurora Cannabis Common Shares (ACB)?

The current stock price of Aurora Cannabis Common Shares (ACB) is $4.27 as of December 20, 2024.

What is the market cap of Aurora Cannabis Common Shares (ACB)?

The market cap of Aurora Cannabis Common Shares (ACB) is approximately 225.0M.

What is Aurora Cannabis Inc. primarily known for?

Aurora Cannabis Inc. is known for the cultivation, production, and sale of high-quality cannabis products for both medical and recreational use.

Where is Aurora Cannabis Inc. headquartered?

Aurora Cannabis Inc. is headquartered in Edmonton, Alberta, Canada.

What are some of the brands under Aurora Cannabis?

Some of the brands under Aurora Cannabis include Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard.

What recent products has Aurora Cannabis launched?

Aurora Cannabis recently launched three new cannabis-infused beverages and resin cartridges in Australia, catering to patient needs with innovative and high-quality products.

What is Aurora's financial outlook for 2024?

Aurora expects to achieve positive free cash flow in calendar 2024 and has recently completed the repayment of nearly $465 million in convertible debt.

What significant acquisitions has Aurora made recently?

Aurora acquired the remaining equity interest in MedReleaf Australia, strengthening its position in the Australian medical cannabis market.

What certifications do Aurora's production facilities hold?

Aurora's production facilities hold EU-GMP and TGA-GMP certifications, ensuring compliance with rigorous international quality standards.

How does Aurora contribute to the U.S. cannabis market?

Aurora's wholly-owned subsidiary, Australis Capital Inc., actively participates in the U.S. cannabis market.

What international operations does Aurora have?

Aurora has expanded internationally through medical cannabis exporting agreements, with a significant presence in Europe and Australia.

How does Aurora ensure the quality of its products?

Aurora ensures the quality of its products through advanced cultivation techniques and compliance with international standards like EU-GMP and TGA-GMP.

Aurora Cannabis Inc. Common Shares

NYSE:ACB

ACB Rankings

ACB Stock Data

225.00M
54.75M
13.04%
7.99%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Edmonton